Full-Time

Senior Systems Analyst

Investor Compliance

Posted on 8/14/2025

Wellington Management

Wellington Management

1,001-5,000 employees

Global asset management for institutional clients

Compensation Overview

$80k - $180k/yr

+ Corporate Bonus + Incentives

Company Historically Provides H1B Sponsorship

Boston, MA, USA

Hybrid

Four days in office per week with one remote day.

Category
IT & Security (2)
,
Required Skills
Python
React.js
Node.js
SQL
Java
Postgres
REST APIs
C/C++
Oracle
Linux/Unix
Requirements
  • Strong analytical and problem-solving skills, with high attention to detail
  • Hands-on knowledge of SQL and relational database technology
  • Comfortable performing in-depth, detailed analysis, including the ability to manipulate and re-examine data from various perspectives to gain comprehensive insights.
  • Strong aptitude for technology and ability to reverse engineer applications
  • Ability to navigate and interpret application log files to troubleshoot issues and gain insight into system behavior, even without deep expertise
  • Excellent written and verbal requirements for functional specifications, use cases, and test plans
  • Strong client relationship skills and proven ability to build consensus
  • Experience working directly with business partners to understand their needs and deliver solutions that meet those needs
  • Change agent, creative, innovative, and focused on continuous improvements
  • Self-motivated and willing to work in an energetic, fast paced team environment
  • Experience supporting critical production applications
  • Prior years of experience as a systems analyst in the financial services industry
  • Understanding of financial instruments such as stocks, bonds, swaps, options, futures, forwards, derivatives, and FX
  • Experience with advanced investment data concepts such as holdings, transactions, security master, analytics, and performance
  • Detailed knowledge and experience of investors workflows in areas of research, valuation, analysis, and portfolio construction
  • Bachelor’s degree is required
  • Use of Linux is a plus
Responsibilities
  • Interact directly with business partners at all levels of the organization to define, analyze and document requirements, as well as set priorities
  • Work hands-on with our Guideline Monitoring application to design and enhance features.
  • Reverse engineering a vendor application to modify its behaviour for our business needs.
  • Ensure quality of product by enforcing high standards in testing and building audit/validation controls
  • Assist in writing test plans to ensure software quality is up to standards
  • Become subject matter expert in our current suite by using application.
  • Act as an escalation point person for support issues that require detailed analysis and management
  • Ensure on time, scalable and high-quality business solutions
  • Provide input into system design to help the programming teams define effort and implementation schedules
  • Provide regular status reporting and issue tracking
Wellington Management

Wellington Management

View

Wellington Management is a global investment management firm that offers equity, fixed income, multi-asset, and alternative investments to both institutional clients (such as pension funds, endowments, foundations, and insurers) and individual investors. It manages assets on behalf of clients, earning fees based on assets under management (AUM) and on investment performance. The firm relies on deep research capabilities and market insights to tailor investment strategies that meet client needs, and it integrates environmental, social, and governance (ESG) factors into its process. What sets Wellington Management apart is its broad suite of investment options combined with a commitment to ESG integration and a client-tailored approach, supported by a culture that emphasizes diversity and inclusion. The company’s goal is to help clients achieve their investment objectives by delivering disciplined, research-driven strategies and sustainable investing over the long term.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

$60B

Headquarters

Boston, Massachusetts

Founded

1933

Simplify Jobs

Simplify's Take

What believers are saying

  • $1.19T AUM as of December 2024 supports scale across 50 countries.
  • Led Encord's $60M Series C to scale AI data platform in 2026.
  • Private credit market exceeds $30T, fueling 2023-launched capabilities.

What critics are saying

  • BlackRock's $11.5T AUM erodes active fees via ETF scale.
  • Renk's €300M blocked revenue writedowns 5.09% stake value.
  • Quince lawsuit triggers $50-100M liability on Series E investment.

What makes Wellington Management unique

  • Launched Absolute Return Global Equity Fund for market-neutral alpha in volatility.
  • Expanded private real estate credit platform in 2025 with Ravi S. Anand leading.
  • Manages $40B in alternatives across 40 funds for institutional clients.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Comprehensive health coverage

Work-life balance

Financial future

Development

Company News

Radio Intereconomía
Apr 14th, 2026
Wellington launches global market neutral fund to capture alpha in volatile environment

Wellington Management has launched the Wellington Absolute Return Global Equity Fund, a UCITS vehicle employing a global market neutral strategy aimed at generating returns above cash with limited exposure to traditional markets. The fund expands Wellington's liquid alternatives offering. The launch comes amid increased market volatility and reduced stability, positioning the fund to capture alpha in challenging conditions through its market-neutral approach to global equities.

AD HOC NEWS Portal Aktiengesellschaft
Apr 12th, 2026
Wellington buys 5% stake in Renk as $339M in delayed defence contracts weigh on cash flow

Wellington Management has acquired a 5.09% stake in German defence supplier Renk Group, signalling confidence despite the company facing significant operational challenges. The US asset manager built its position through direct share purchases and equity swaps. Renk is currently contending with approximately €300 million in blocked revenue due to delayed deliveries and missing export licenses. Around €200 million in planned sales has been pushed to 2026, whilst €80-100 million in orders for Israeli tank gearbox systems await German export approval. The cash flow pressure is evident, with free cash flow reaching only €67 million last fiscal year, well below the company's 80% conversion target. Shares fell 4.34% to €52.05, extending year-to-date losses to nearly 6%. Despite near-term challenges, Renk maintains a record order backlog of €6.68 billion.

Voyager Therapeutics
Apr 10th, 2026
Voyager Therapeutics Raises $60 Million in Oversubscribed Series B Financing | Voyager Therapeutics Inc.

Gene Therapy Leader to Advance Broad Product Pipeline & AAV Product Engine   Cambridge, Mass., April 13, 2015 – Voyager Therapeutics , a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS), today announced the successful

Business Wire
Apr 2nd, 2026
Cyclerion Therapeutics and Korsana Biosciences Announce Merger Agreement

Cyclerion Therapeutics, Inc. (“Cyclerion”) (Nasdaq: CYCN) and Korsana Biosciences, Inc. (“Korsana”), a privately-held biotechnology company discovering and d...

医谷网
Mar 23rd, 2026
London gene therapy firm NightstaRx raises $45M to advance blindness treatment trials

NightstaRx, a London-based ophthalmology company developing gene therapies for inherited retinal diseases, has raised $45 million in Series C funding. Wellington Management Company and Redmile Group led the round, with participation from existing investors Syncona and New Enterprise Associates. Founded in 2013, Nightstar has four drug candidates targeting conditions including choroideremia, X-linked retinitis pigmentosa and macular degeneration. Its lead candidate, NSR AAV-REP1, uses an adeno-associated virus vector to deliver the REP-1 gene to retinal cells, potentially offering a one-time treatment for choroideremia, which causes progressive blindness. The therapy is currently in phase 1/2 trials, with positive results from 14 patients published in The Lancet. The funding will advance NSR AAV-REP1 into phase 3 trials and progress two other candidates into phase 1/2 studies.

INACTIVE